Initiation of a collaboration with Paris-Diderot University to discover new drugs against adenoviruses

Published on 18/10/2017

ENYO Pharma announces its collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d’Hématologie), leaded by IDF Innov SATT, to discover new drugs against adenoviruses. The collaboration, built upon ENYO Pharma’s unique approach inspired by viruses, will identify new human cellular targets and pathway essential for replication of adenoviruses. This information will help to select experimental or clinical-stage small molecules that will be tested in a drug repositioning strategy. ENYO pharma will provide its peptide and small molecule libraries to the University team which will screen and analyse their impact on adenoviruses’ biology.

Read next in 'Latest news'

• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
• Swiss NASH Foundation sponsorship
• ENYO Pharma in the Top 50 of the EIC ScalingUp List